I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
- Strong cash position of $168.6M providing runway into 2027
- Significant reduction in net loss to $3.2M in Q1 2025 from $16.3M in Q1 2024
- R&D expenses decreased substantially to $0.8M from $6.1M year-over-year
- Ahead-of-schedule enrollment in Phase 1b givastomig trial
- Higher interest income of $1.9M compared to $0.7M year-over-year
- Administrative expenses increased to $4.5M from $2.4M year-over-year
Insights
I-Mab's Q1 results show improved financials, narrowed focus on lead cancer program, with key clinical data expected in 2026.
I-Mab's Q1 2025 financials reveal a strategic realignment paying off following their January decision to prioritize givastomig (a CLDN18.2 x 4-1BB bispecific antibody) as their lead program. This focus has accelerated their clinical timeline, with enrollment in the first Phase 1b expansion cohort now completed ahead of schedule.
The financial picture shows significant improvement compared to Q1 2024. R&D expenses dropped dramatically from
Most importantly, their cash position of
The company's strategy now centers on gastric cancer, which affects over 250,000 patients globally. Their upcoming mini-oral presentation at ESMO GI in July 2025 will present new combination data for givastomig with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma, suggesting early confidence in these results. The full data from both expansion cohorts (n=40) is expected in 1H 2026.
This leaner, more focused approach following their China divestiture (completed April 2024) has enabled I-Mab to concentrate resources on their most promising asset while significantly reducing their cash burn rate. While specific clinical efficacy data isn't provided yet, the accelerated enrollment and selection for presentation at ESMO GI suggest positive investigator interest in the program.
- Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progress
- New givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, Spain
- Strong financial position supported by
$168.6 million of cash and cash equivalents, and short-term investments as of March 31, 2025; provides runway into 2027, through expected clinical readouts for givastomig
ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three months ended March 31, 2025, and highlighted recent pipeline progress and business updates.
“2025 is off to a strong start for I-Mab. Designation of givastomig as our lead program has enabled us to unlock significant value for the Company by considerably accelerating our Phase 1b program, as we work to improve the care of patients with gastric cancers, which impact more than 250,000 people globally,” said Sean Fu, PhD, Chief Executive Officer of I-Mab. “Driven by study momentum and investigator interest, we have completed patient enrollment in the first of two Phase 1b dose expansion cohorts ahead of schedule. We expect to share data on both cohorts in 1H 2026. We believe the combination of significant progress in our givastomig program, substantial cash balance, streamlined operations, and new U.S.-based business model positions I-Mab to deliver for both patients and our investors.”
Pipeline Overview and Anticipated Upcoming Milestones
Upcoming anticipated milestones for givastomig (CLDN18.2 x 4-1BB bispecific), prioritized to be I-Mab’s lead program in January 2025:
- July 2025: Presentation of new givastomig dose escalation combination data on U.S. patients at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, being held July 2-5 in Barcelona, Spain
Details of the ESMO GI Mini Oral Presentation:
Title: Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)
Speaker: Samuel J. Klempner, MD, Associate Professor of Medicine, Massachusetts General Hospital
Presentation Number: 388MO
Date and Time: Wednesday, July 2nd at 16:50 CEST (10:50am EST)
- 1H 2026: Presentation of data from givastomig dose expansion cohorts (n=40)
Enrollment in the ongoing dose expansion study for givastomig is progressing ahead of schedule. In addition, the Company anticipates updates in 2026 for two programs being developed with its partners: uliledlimab (monoclonal antibody targeting CD73); and ragistomig (PD-L1 x 4-1BB bispecific).
First Quarter 2025 Financial Results – In connection with the divestiture of its Greater China assets and business operations, I-Mab’s first quarter 2024 amounts have been recast to conform to the discontinued operations presentation. Additionally, certain non-recurring costs occurred during the first quarter of 2024 that impact quarter-over-quarter comparisons.
Cash Position
As of March 31, 2025, the Company had cash and cash equivalents, and short-term investments of
Shares Outstanding
As of March 31, 2025, the Company had 187,818,796 ordinary shares issued and outstanding, representing the equivalent of 81,660,346 ADSs, assuming the conversion of all ordinary shares into ADSs.
Research and Development Expenses
Research and development expenses were
Administrative Expenses
Administrative expenses were
Interest Income
Interest income was
Other Income (Expenses), Net
Other income (expenses), net were
Equity in Loss of Affiliates
Equity in loss of affiliates was
Net Loss from Continuing Operations
Net loss from continuing operations was
Net Loss from Discontinued Operations
On April 2, 2024, the Company closed the China divestiture announced on February 7, 2024 (the “Transaction”). In accordance with ASC 205-20, the Company determined that the Transaction represented a strategic shift that had a major effect on the business and therefore, met the criteria for classification as discontinued operations. As a result, the Company recognized a loss from discontinued operations of
Net Loss
Net loss was
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (“CLDN18.2”)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (“1L”) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.
The ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data.
Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s pipeline and clinical development of I-Mab’s drug candidates, including givastomig; the projected advancement of the Company’s portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the Company’s expectations regarding its cash runway; the timing and progress of studies and trials (including with respect to the patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the “Risk Factors” section in I-Mab’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
| I-Mab | ||||||||
| Consolidated Balance Sheets | ||||||||
| (Unaudited; All amounts in thousands, except for par value and share data) | ||||||||
| As of March 31, | As of December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 53,597 | $ | 68,263 | ||||
| Short-term investments | 115,025 | 105,135 | ||||||
| Prepayments and other receivables | 4,611 | 3,295 | ||||||
| Total current assets | 173,233 | 176,693 | ||||||
| Property, equipment and software | 188 | 201 | ||||||
| Operating lease right-of-use assets | 3,404 | 3,597 | ||||||
| Investments at fair value, available-for-sale debt securities (amortized cost of | 30,824 | 30,824 | ||||||
| Other non-current assets | 1,292 | 1,365 | ||||||
| Total assets | $ | 208,941 | $ | 212,680 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accruals and other payables | $ | 6,916 | $ | 7,638 | ||||
| Operating lease liabilities, current | 835 | 816 | ||||||
| Total current liabilities | 7,751 | 8,454 | ||||||
| Operating lease liabilities, non-current | 2,849 | 3,066 | ||||||
| Total liabilities | 10,600 | 11,520 | ||||||
| Shareholders’ equity | ||||||||
| Ordinary shares ( | 19 | 19 | ||||||
| Treasury stock | (5,881 | ) | (6,225 | ) | ||||
| Additional paid-in capital | 1,460,005 | 1,460,021 | ||||||
| Accumulated other comprehensive income | 33,387 | 33,384 | ||||||
| Accumulated deficit | (1,289,189 | ) | (1,286,039 | ) | ||||
| Total shareholders’ equity | 198,341 | 201,160 | ||||||
| Total liabilities and shareholders’ equity | $ | 208,941 | $ | 212,680 | ||||
| I-Mab | ||||||||
| Consolidated Statements of Comprehensive Loss | ||||||||
| (Unaudited; All amounts in thousands, except for share and per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues | ||||||||
| Licensing and collaboration revenue | $ | — | $ | — | ||||
| Total revenues | — | — | ||||||
| Expenses | ||||||||
| Research and development expenses(1) | (777 | ) | (6,062 | ) | ||||
| Administrative expenses(2) | (4,489 | ) | (2,441 | ) | ||||
| Total expenses | (5,266 | ) | (8,503 | ) | ||||
| Loss from operations | (5,266 | ) | (8,503 | ) | ||||
| Interest income | 1,872 | 709 | ||||||
| Other income (expenses), net | 244 | (587 | ) | |||||
| Equity in loss of affiliates(3) | — | (1,038 | ) | |||||
| Loss from continuing operations before income tax expense | (3,150 | ) | (9,419 | ) | ||||
| Income tax expense | — | — | ||||||
| Loss from continuing operations | (3,150 | ) | (9,419 | ) | ||||
| Discontinued operations: | ||||||||
| Loss from operations of discontinued operations(4) | — | (6,898 | ) | |||||
| Income tax expense | — | — | ||||||
| Loss from discontinued operations | — | (6,898 | ) | |||||
| Net loss | (3,150 | ) | (16,317 | ) | ||||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation adjustments, net of tax | 3 | 1,025 | ||||||
| Total comprehensive loss | $ | (3,147 | ) | $ | (15,292 | ) | ||
| Weighted-average number of ordinary shares used in calculating net loss per share - basic and diluted | 187,679,483 | 185,858,408 | ||||||
| Net loss from continuing operations per share - basic and diluted | $ | (0.02 | ) | $ | (0.05 | ) | ||
| Net loss from discontinued operations per share - basic and diluted | $ | — | $ | (0.04 | ) | |||
| Net loss per share - basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | ||
| Net loss from continuing operations per ADS(5) - basic and diluted | $ | (0.04 | ) | $ | (0.12 | ) | ||
| Net loss from discontinued operations per ADS(5) - basic and diluted | $ | — | $ | (0.09 | ) | |||
| Net loss per ADS(5) - basic and diluted | $ | (0.04 | ) | $ | (0.21 | ) | ||
(1) Includes share-based compensation expense of
(2) Includes share-based compensation expense of
(3) Includes share-based compensation expense of
(4) Includes share-based compensation expense of
(5) Each 10 ADSs represents 23 ordinary shares.
FAQ
What were IMAB's Q1 2025 financial results?
What is the status of IMAB's givastomig clinical trial?
How long will IMAB's current cash position last?
What is IMAB's lead drug candidate?
How many shares does IMAB have outstanding as of Q1 2025?
